Key in the IL‐4/IL‐13 axis is the IL‐4Rα signaling which has been identified as a potential target for asthma therapies.12, 13, 14 Deficiency of IL‐4Rα in allergen‐sensitized mice shows reduced allergen‐induced symptoms such as AHR, eosinophilia, and mucus hyperplasia in vivo.15, 16, 17 We and others have also illustrated various cell‐specific roles of IL‐4Rα signaling during the development of allergic disease pathology.11, 18, 19, 20, 21 However, limited successful anti‐TH2‐based treatments for asthma calls for better understanding of the mechanisms involved in successful therapy. This evidence concerns the gene IL13 and allergic disease.